Evotec SE (EVO)

NASDAQ: EVO · IEX Real-Time Price · USD
9.19
+0.45 (5.15%)
At close: Dec 1, 2022 4:00 PM
9.39
+0.20 (2.18%)
Pre-market: Dec 2, 2022 4:21 AM EST
5.15%
Market Cap 3.23B
Revenue (ttm) 697.83M
Net Income (ttm) -179.93M
Shares Out 176.70M
EPS (ttm) 0.02
PE Ratio 459.50
Forward PE 89.29
Dividend n/a
Ex-Dividend Date n/a
Volume 120,931
Open 9.33
Previous Close 8.74
Day's Range 9.13 - 9.4
52-Week Range 7.83 - 25.29
Beta 1.15
Analysts Buy
Price Target 16.50 (+79.5%)
Earnings Date Nov 9, 2022

About EVO

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bri... [Read more]

Industry Drug Manufacturers-Specialty & Generic
IPO Date Nov 4, 2021
CEO Werner Lanthaler
Employees 4,715
Stock Exchange NASDAQ
Ticker Symbol EVO
Full Company Profile

Financial Performance

In 2021, Evotec SE's revenue was 618.03 million, an increase of 23.38% compared to the previous year's 500.92 million. Earnings were 215.51 million, an increase of 3,332.78%.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for EVO stock is "Buy." The 12-month stock price forecast is 16.5, which is an increase of 79.54% from the latest price.

Price Target
$16.5
(79.54% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Evotec SE to Announce Results for the First Nine Months 2022 on 09 November 2022

HAMBURG, GERMANY / ACCESSWIRE / November 3, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first nine months 202...

4 weeks ago - Accesswire

Evotec Completes Acquisition of Central Glass Germany

AS EVOTEC DRUG SUBSTANCE (GERMANY) GMBH, THE ACQUISITION STRENGTHENS EVOTEC'S CLINICAL AND COMMERCIAL DRUG SUBSTANCE MANUFACTURING CAPACITY AND CAPABILITY ESPECIALLY FOR RARE DISEASES AND PRECISION THER...

4 weeks ago - Accesswire

Evotec Presents Paradigm Shift in Biologics at Capital Markets Day

TOGETHER FOR MEDICINES THAT MATTER: A PARADIGM SHIFT TO UNLOCK NEW MARKETS AND OPPORTUNITIES FOR GLOBAL ACCESS TO BIOLOGICS BY APPLYING A FULLY INTEGRATED, END-TO-END CONTINUOUS BIOMANUFACTURING PROCESS...

1 month ago - Accesswire

Evotec, CDP Venture Capital and Angelini Ventures Launch Translational Partnership 'Extend' with Leading Italian Acad...

EXTEND AIMS TO DEVELOP DRUG DISCOVERY PARTNERSHIPS WITH LEADING ACADEMIC INSTITUTIONS FROM ITALY TO ACCELERATE THEIR PROMISING THERAPEUTICS FOR COMMERCIALISATION HAMBURG, GERMANY / ACCESSWIRE / October ...

1 month ago - Accesswire

Evotec Enters Partnership with Hannover Medical School to Create Molecular Patient Database in Autoimmune Diseases

GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF SJÖGREN'S SYNDROME ("SJS") AND SYSTEMIC LUPUS ERYTHEMATOSUS ("SLE") HANNOVER MEDICAL SCHOOL ("MHH") WILL COLLECT BIOSAMPL...

1 month ago - Accesswire

Evotec launches PanOmics Data Analysis Platform PanHunter at Bio-IT World

PANHUNTER EMPOWERS ANY SCIENTIST TO ACCESS AND ANALYSE DEEP BIOLOGICAL AND CLINICAL DATA INCLUDING IN PARTICULAR HUGE PANOMICS DATA SETS PANHUNTER ACCELERATES THE R&D PROCESS AND IMPROVES SUCCESS RATES ...

1 month ago - Accesswire

Evotec and TIAP Expand LAB150 BRIDGE Partnership to Include Amgen

AMGEN TO JOIN LAB150 TO BUILD CANADA'S NEXT GENERATION OF LIFE SCIENCE COMPANIES HAMBURG, GERMANY and TORONTO, ON / ACCESSWIRE / October 17, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX,...

1 month ago - Accesswire

TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen

TORONTO, Canada & HAMBURG, Germany--(BUSINESS WIRE)-- #LifeSciences--Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASD...

1 month ago - Business Wire

Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program

JUST - EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS ANTI-PLAGUE MABS EVOTEC WILL PROVIDE PRE-CLINICAL AND CLINICAL TRIAL SERVICES HAMBURG, GERMANT / ...

2 months ago - Accesswire

Evotec Initiates Ground-Breaking for New Biologics Facility J.POD(R) Toulouse, France (EU)

J.POD ® TOULOUSE, FRANCE (EU) BRINGS A DISRUPTIVE, FLEXIBLY SCALABLE BIOLOGICS MANUFACTURING TECHNOLOGY TO THE REGION THE MANUFACTURING FACILITY IS EXPECTED TO BE OPERATIONAL IN H2 2024 HAMBURG, GERMANY...

2 months ago - Accesswire

Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany

EXPANSION OF CGMP DRUG SUBSTANCE MANUFACTURING PLATFORM WILL CREATE A CLEAR PATH TO THE MARKET FOR RARE DISEASES AND PRECISION THERAPEUTICS EVOTEC GAINS A FULLY OPERATIONAL EU GMP CERTIFIED FACILITY IN ...

3 months ago - Accesswire

Just - Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303

JUST - EVOTEC BIOLOGICS WILL APPLY ITS FULLY INTEGRATED TECHNOLOGY PLATFORM TO DEVELOP AN OPTIMISED COMMERCIAL PROCESS FOR ALPN-303, A DUAL BAFF/APRIL INHIBITOR FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND OTHE...

Other symbols: ALPN
3 months ago - Accesswire

Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303

HAMBURG, Germany & SEATTLE--(BUSINESS WIRE)--Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today announced that ...

Other symbols: ALPN
3 months ago - Business Wire

Evotec SE Reports First Half-year 2022 Results on 11 August 2022

HAMBURG, GERMANY / ACCESSWIRE / August 4, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first half-year 2022 ...

3 months ago - Accesswire

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

INGELHEIM, Germany & HAMBURG, Germany & MARCY-L'ÉTOILE, France--(BUSINESS WIRE)--Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt ...

4 months ago - Business Wire

Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance

HAMBURG, GERMANY and FRANCE / ACCESSWIRE / July 6, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), Boehringer Ingelheim, a leading research-driven biophar...

4 months ago - Accesswire

Evotec Completes Acquisition of Rigenerand

AS "EVOTEC CELL ACCELERATOR", THE HIGH-QUALITY CGMP CELL THERAPY MANUFACTURING SITE ADDS CAPACITY AND CAPABILITY EVOTEC'S EVO CELLS PLATFORM INTEGRATES INNOVATIVE OFF-THE-SHELF IPSC-BASED CELL THERAPY D...

4 months ago - Accesswire

Evotec SE Reports Results of Annual General Meeting 2022

ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY CAMILLA MACAPILI LANGUILLE ELECTED AS NEW MEMBER OF THE SUPERVISORY BOARD; KASIM KUTAY RESIGNS FROM SUPERVISORY BOARD AUTHORISED CAPITAL 2022 RESOLVED...

5 months ago - Accesswire

Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J

Evotec (EVO) signs a collaboration agreement with Janssen, a wholly owned subsidiary of J&J, for discovering novel drugs in the field of protein homeostasis. Shares down.

5 months ago - Zacks Investment Research

Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibitio...

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2A receptor antagonist co-invented and d...

Other symbols: EXAI
5 months ago - Business Wire

Evotec Enters a Drug Discovery Collaboration with Janssen

STRATEGIC PARTNERSHIP LEVERAGES EVOTEC'S PROPRIETARY PLATFORM CAPABILITIES IN THE FIELD OF PROTEIN HOMEOSTASIS HAMBURG, GERMANY / ACCESSWIRE / June 14, 2022 / Evotec SE (FRA:EVT)(MDAX/TecDAX)(ISIN:DE000...

5 months ago - Accesswire

Evotec Adds Cell Therapy Manufacturing Facility with Acquisition of Rigenerand

CELLS PLATFORM INTEGRATES INNOVATIVE OFF-THE-SHELF IPSC CELL THERAPY DISCOVERY WITH DEVELOPMENT AND MANUFACTURING HAMBURG, GERMANY / ACCESSWIRE / May 30, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT,...

6 months ago - Accesswire

Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology

THE MULTI-TARGET RESEARCH AND DEVELOPMENT PARTNERSHIP WILL FOCUS ON SEVERE SKIN DISEASES, INCLUDING IMMUNE-MEDIATED INFLAMMATORY CONDITIONS SUCH AS ATOPIC DERMATITIS AND NON-MELANOMA SKIN CANCER SUCH AS...

6 months ago - Accesswire

Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a...

PARTNERSHIP LEVERAGES IPSC-BASED BETA CELLS FROM EVOTEC'S QRBETA INITIATIVE COMBINED WITH SERNOVA'S PROPRIETARY IMPLANTABLE CELL POUCH™ DEVICE THE GOAL IS THE DEVELOPMENT AND COMMERCIALISATION OF AN OFF...

6 months ago - Accesswire

Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership

HAMBURG, GERMANY / ACCESSWIRE / May 10, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces today that the Company has extended and exp...

6 months ago - Accesswire